Sex
HCG (Human Chorionic Gonadotropin)
Glycoprotein hormone · LH/FSH receptor ligand · Recombinant
FDA · APPROVED (NOVAREL/PREGNYL)
Half-life
~1 days
Long
minsdays
Route
SubQ injection
Evidence
Approved therapeutic
Risk
Standard
Overview
Known for
Mechanism
Key facts
Format
Lyophilized powder
Mechanism targets
Classification
Authoritative
Supply & nature
ExogenousExogenous
FDA category
Approved (Novarel/Pregnyl)
Evidence & standing
Evidence base
Approved therapeutic
Risk level
Standard
Best studies
5 references
Dosage & protocol
Typical dose
250-500 IU
Research range
500–2000 IU
Cycle
Per fertility or HPTA protocol
Onset
10 days first effects
Full effect
56 days
Half-life
~24-36h
~24-36 hours (biphasic: initial 6hr, terminal 24-36hr)
Protocol
Time to effects
Recommended vial
Reference figures only
Dosing reflects published laboratory protocols and is not guidance for use in any living subject.
Safety
Handle with research caution
Storage & handling
Lyophilised
12–24 months
2–8°C
Reconstituted
30–60 days
2–8°C
Videos & talks
Independent educational content from researchers, clinicians and science communicators — not affiliated with Pepnerd.
Educational resources only. Videos are independent third-party content. Pepnerd is not affiliated with these creators and does not endorse or make claims based on their content. All products are for in-vitro research.
